<DOC>
	<DOCNO>NCT01256853</DOCNO>
	<brief_summary>This phase I , dose escalation trial MVA-EBNA1/LMP2 vaccine across pre-defined range dose patient remission EBV+ nasopharyngeal carcinoma ( NPC ) .</brief_summary>
	<brief_title>Modified Vaccinia Ankara ( MVA ) Vaccine Study</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Epstein-Barr Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically confirm NPC , presence EBV within malignant cell demonstrate ( 1 ) EBER ( EBV early RNA ) situ hybridisation 50 % malignant cell , ( 2 ) undifferentiated poorly differentiate carcinoma histology association raise serum titer IgA EBV VCA . Patients remission disease , ie complete response ( CR ) unconfirmed complete response ( CRu ) . Completion standard therapy malignancy least 12 week trial entry . Written inform consent ability patient cooperate treatment follow must ensure document . Age great 18 year . World Health Organisation ( WHO ) performance status 0 1 Life expectancy least 4 month . Haematological biochemical index ( measurement must perform within 28 day prior patient go study ) : Haemoglobin ( Hb ) &gt; 10.0 g/dl Lymphocytes &gt; 1.0 x 109/L ( low limit normal range institutional laboratory ) Neutrophils ≥ 1.5 x 109/L Platelets ( Plts ) ≥ 100 x 109/L baseline liver function test : Serum bilirubin ≤ 1.5 x upper normal limit Serum alkaline phosphatase , alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &lt; 1.5 x ULN . baseline renal function test : calculate creatinine clearance &gt; 50ml/min Female patient childbearing potential eligible , provide negative pregnancy test prior enrolment agree use appropriate medically approve contraception study six month last vaccination . Male patient must agree use appropriate medically approve contraception study six month last vaccination . Receiving current chemotherapy radiotherapy , receive within 12 week trial entry . Known chronic active infection Hepatitis B , Hepatitis C Human Immunodeficiency Virus ( HIV ) . Current active autoimmune disease . Current active skin disease require therapy ( psoriasis , eczema etc ) . Ongoing active infection . History anaphylaxis severe allergy vaccination . Allergy egg egg product . Previous myeloablative therapy follow autologous allogeneic haematopoietic stem cell transplant . Patients splenectomy splenic irradiation , know splenic dysfunction . Receiving current immunosuppressive medication , include corticosteroid . Pregnant lactating woman . Ongoing toxic manifestation previous treatment . Exceptions alopecia certain Grade 1 toxicity opinion Investigator Cancer Research UK exclude patient . Major thoracic and/or abdominal surgery precede four week patient yet recover . Patients condition Investigator 's opinion would make patient good candidate clinical trial . Concurrent congestive heart failure prior history class III/ IV cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>histologically confirm EBV+ NPC patient</keyword>
</DOC>